title: Factor V Leiden mutation: a treatable etiology for sporadic and recurrent pregnancy loss.
abstract: OBJECTIVE
  We hypothesized that the thrombophilic G1691A factor V Leiden (FVL) gene mutation was a common, significant, and treatable cause of sporadic and recurrent pregnancy loss (RPL).
  
  
  METHODS
  We compared the frequency of the FVL mutation in 141 women with >or=1 pregnancy and 1 sporadic pregnancy loss (308 live births, 141 pregnancy losses), 44 women with >or=1 pregnancy and >or=3 pregnancy losses (105 live births, 180 pregnancy losses), and 638 women with >or=1 live birth pregnancy and 0 pregnancy loss (1553 live births).
  
  
  METHODS
  Outpatient Clinical Research Center.
  
  
  METHODS
  A total of 823 caucasian women with consecutive measures of the FVL mutation.
  
  
  METHODS
  We used polymerase chain reaction techniques to characterize the thrombophilic FVL G1691A gene mutation.
  
  
  RESULTS
  Of the 638 controls, 47 (7.4%) had FVL heterozygosity versus 16 heterozygous and 2 homozygous FVL cases (18/141, 12.8%) in 141 women with 1 sporadic pregnancy loss versus 9/44 RPL cases (20.5%, 8 heterozygous and 1 homozygous FVL). The FVL frequency in cases with 1 sporadic pregnancy loss (18/141, 12.8%) did not differ from RPL cases (9/44, 20.45%).
  
  
  CONCLUSIONS
  After unexplained sporadic pregnancy loss, as well as after RPL, to provide the option to prospectively optimize subsequent live birth outcomes with low-molecular-weight heparin thromboprophylaxis, we suggest that measurements be done of the FVL mutation, a treatable etiology for sporadic pregnancy loss as well as for RPL.
authors.affiliation: Cholesterol Center, Jewish Hospital, Cincinnati, Ohio 45229, USA. glueckch@healthall.com
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Glueck
authors.forename: Srikant
authors.initials: S
authors.lastname: Gogenini
authors.forename: Jitender
authors.initials: J
authors.lastname: Munjal
authors.forename: Trent
authors.initials: T
authors.lastname: Tracy
authors.forename: Joel
authors.initials: J
authors.lastname: Pranikoff
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
mesh_terms: D000026:Abortion, Habitual / Q000235:genetics* / Q000628:therapy*; D017677:Age Distribution; D000925:Anticoagulants / Q000627:therapeutic use; D016022:Case-Control Studies; D020964:Embryo Loss / Q000235:genetics* / Q000628:therapy*; D005165:Factor V / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D005865:Gestational Age; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D009154:Mutation; D011247:Pregnancy; D011255:Pregnancy Maintenance / Q000235:genetics; D019851:Thrombophilia / Q000235:genetics / Q000517:prevention & control / Q000628:therapy
chemical_list: D000925:Anticoagulants; C095381:factor V Leiden; D005165:Factor V